Underwriters Shouldn't Be Reading Lab Reports
Underwriters Shouldn't Be Reading Lab Reports The Manual COA Problem Is Becoming One of the Biggest Compliance Gaps in Regulated Payment...
On November 5, 2024, Florida voters decided against Amendment 3, which would have legalized adult-use, or recreational, cannabis. With only 55.9% in favor, the measure fell short of the required 60% support, delivering a significant blow to the $32 billion regulated cannabis industry in the U.S. and a particular setback for Trulieve Cannabis Corp. This Florida-based multistate operator had invested over $144 million to get Amendment 3 on the ballot, hoping to expand Florida’s market from medical-only to recreational.
As the largest medical-only cannabis market in the U.S., Florida represented a major opportunity for industry growth. The amendment’s failure reflects both the state’s political climate and persistent opposition from Governor Ron DeSantis, who actively campaigned against it. DeSantis argued that the amendment was more about creating a “monopoly” for a few large operators, like Trulieve, rather than truly opening up a competitive adult-use market.
Florida’s cannabis advocates faced numerous obstacles. Beyond needing a supermajority, they contended with significant opposition from conservative leaders. DeSantis used millions of taxpayer dollars from an opioid settlement fund to run ads opposing Amendment 3, a move that galvanized critics but resonated with many voters who were cautious about industry concentration.
In a familiar trend, Florida voters followed a pattern seen in Ohio in 2015, where legalization proposals faced criticism for appearing to favor a small group of companies. Such initiatives often raise concerns about market fairness and consumer choice, with critics arguing that they could concentrate control among a limited number of operators.
Despite the outcome, advocates believe the widespread public support for Amendment 3—just shy of the supermajority threshold—demonstrates that attitudes toward cannabis legalization in Florida are shifting.
Though disappointed, cannabis industry leaders remain optimistic about the future. Trulieve CEO Kim Rivers praised the efforts of supporters across the state and emphasized Trulieve’s commitment to the cause. “Proud to have fought the fight,” she said. “Onward to ensuring safe access for adults and decriminalization for personal use.”
The Smart & Safe Florida campaign, which organized efforts to support Amendment 3, echoed Rivers’ sentiment. They issued a statement highlighting the “historic, bipartisan campaign” that showed how legalization resonated with Floridians. David Culver, chief of policy at the U.S. Cannabis Council, added, “This isn’t the end in Florida. We’re ready to work with legislators to make safe, regulated cannabis a reality.”
With the defeat of Amendment 3, Florida’s cannabis industry will remain limited to medical use, currently serviced by about 20 licensed operators. These include multistate cannabis operators like Ayr Wellness, Curaleaf Holdings, Green Thumb Industries, and Trulieve. Together, these companies operate nearly 700 medical dispensaries across the state.
The amendment’s failure also affects more than just current operators. In 2023, 73 applicants paid significant fees to secure positions for new medical marijuana licenses, but the timeline for reviewing these applications remains uncertain. The cap on permits is tied to the number of patients in Florida’s registry, leaving aspiring operators in a holding pattern.
While Amendment 3’s defeat prevents immediate changes, it likely won’t be the last effort to legalize adult-use cannabis in Florida. The widespread support, even if below 60%, suggests there’s a strong demand for reform among Floridians. Advocates may seek a new path to legalization, possibly through future ballot measures that emphasize transparency, fair market access, and regulatory oversight.
The defeat also poses questions for the cannabis industry’s larger legalization efforts across the United States. Florida’s decision follows similar outcomes in conservative states, hinting at potential barriers that legalization campaigns could face elsewhere. Despite the loss, industry advocates are prepared to continue engaging with both voters and political leaders in Florida, determined to address concerns about market concentration and fair access.
In the meantime, the 20 licensed medical operators will continue to serve qualified patients in Florida, focusing on expanding access to medical cannabis. The push for adult-use legalization will likely continue as advocates regroup, strategize, and work toward a more inclusive approach that resonates with a larger share of the state’s conservative voter base.
As the conversation around cannabis reform evolves, Florida remains a key battleground for the industry. Advocates see this setback as part of a larger journey toward achieving safe, regulated access to cannabis across the country.
